In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi - Wikidata - wikimedia - TriplyDB

In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi

In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi

http://www.wikidata.org/entity/Q28343817

about

Pharmacokinetics and pharmacodynamics of antifungals in children: clinical implications Invasive infections caused by Trichosporon species and Geotrichum capitatum in patients with hematological malignancies: a retrospective multicenter study from Italy and review of the literature In vitro activity of A-192411.29, a novel antifungal lipopeptide An Optimized Lock Solution Containing Micafungin, Ethanol and Doxycycline Inhibits Candida albicans and Mixed C. albicans - Staphyloccoccus aureus Biofilms Safety and pharmacokinetics of repeat-dose micafungin in young infants.Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant.Caspofungin use in patients with invasive candidiasis caused by common non-albicans Candida species: review of the caspofungin database.Peptide-based Antifungal Therapies against Emerging Infections.Safety, tolerability, and pharmacokinetics of Micafungin (FK463) in febrile neutropenic pediatric patients.A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan.Micafungin.Synergy, pharmacodynamics, and time-sequenced ultrastructural changes of the interaction between nikkomycin Z and the echinocandin FK463 against Aspergillus fumigatus.Compartmental pharmacokinetics and tissue distribution of the antifungal echinocandin lipopeptide micafungin (FK463) in rabbits.Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis.Intrapulmonary pharmacokinetics and pharmacodynamics of micafungin in adult lung transplant patients New investigational antifungal agents for treating invasive fungal infections.Antifungal pharmacodynamics: review of the literature and clinical applications.Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits.In vitro activity of micafungin (FK-463) against Candida spp.: microdilution, time-kill, and postantifungal-effect studies Investigational antifungal agents.Overexpression of Candida albicans CDR1, CDR2, or MDR1 does not produce significant changes in echinocandin susceptibility Efficacy of micafungin alone or in combination against systemic murine aspergillosis.Micafungin in the treatment of invasive candidiasis and invasive aspergillosis Infections caused by Fusarium species.New and emerging antifungal agents: impact on respiratory infections.Steady-state pharmacokinetics of micafungin and voriconazole after separate and concomitant dosing in healthy adults Altered Micafungin Pharmacokinetics in Intensive Care Unit Patients Micafungin: pharmacology, experimental therapeutics and clinical applications.Micafungin: the US perspective.Comparative in vitro activities of caspofungin and micafungin, determined using the method of the European Committee on Antimicrobial Susceptibility Testing, against yeast isolates obtained in France in 2005-2006 Echinocandin antifungals: review and update.Emerging echinocandins for treatment of invasive fungal infections.Newer triazole antifungal agents: pharmacology, spectrum, clinical efficacy and limitations.Efficacy of SPK-843, a novel polyene antifungal, in comparison with amphotericin B, liposomal amphotericin B, and micafungin against murine pulmonary aspergillosis Developments in the treatment of candidiasis: more choices and new challenges.Micafungin: a new echinocandin antifungal.The echinocandin micafungin: a review of the pharmacology, spectrum of activity, clinical efficacy and safety.Micafungin activity against Candida albicans with diverse azole resistance phenotypes.Micafungin sodium, the second of the echinocandin class of antifungals: theory and practice.Micafungin for the prophylaxis and treatment of Candida infections.

P2860

Q27025299-19592B68-BF1C-4969-B9A4-7F38D3026D69 Q28243864-42A6FF32-0C30-4DC5-9C40-B7C48273B19A Q28344147-80C605BF-DD53-469C-A271-7A2105DA2398 Q28552679-8F478121-AAD0-4663-8E5C-06E3FED4BE17 Q30433612-999CBC26-1ED0-47A6-981C-B92E7EC9B3F5 Q33722115-BC8B312E-E912-406A-A742-AB493DFF91A6 Q33826372-E83C2A11-05BE-4540-8B86-6D876DCA3879 Q33862289-E508BC9C-8997-4C63-B2F1-C932EA02BD80 Q33938201-6F3F5728-6E03-45C4-AE6E-6ED2D50D725D Q33980368-4D646F7B-9ECD-4088-8C4C-A16410F3EDF2 Q33981019-92F9858D-FB07-4E78-8F7F-2F62364F3574 Q33983499-07BC9714-3F31-45F6-A18E-DA9866846675 Q33983506-F547C417-4323-49C2-A55C-65B30EC509D1 Q34006585-67A00F3F-0406-49CF-BDDB-B274FD8263E3 Q34045450-5E7BF558-FD39-4332-B3F5-D0DB6C913503 Q34075014-2ACE920B-D2C1-4FA3-8036-F0A21AA3E618 Q34083129-1D39F177-012C-4E4D-B3C9-342F4A7B829A Q34108880-94BB048A-830B-4BD5-8999-8BBD5FB4542A Q34253266-8065B2D4-5FBD-4943-8521-A04FC80D2D89 Q34335243-F9C4DCDC-F152-4DCA-84C9-A16BA6A1DD6B Q34510707-503E455D-4F42-4A16-9DFC-9A69F64881A7 Q34884594-E042E085-0C8A-41FE-BBB2-5ED87E438DE7 Q35026516-1536860E-FF97-4251-9FEE-9BE61A27884C Q35622021-89716312-089F-4713-870D-A738271681DF Q35627629-462D0FE5-84F2-4FAE-A23D-0713B6FB2399 Q35635928-F7AB14CE-669C-4A8F-8405-460C96031897 Q35860004-1ACAB645-D30B-4D06-A05A-7B46C0F01B65 Q36120798-338DCC02-9FEE-41F8-8E67-6219DD86FC1F Q36140652-A06ACA69-48D7-4BC0-9F39-37FCBADD82B2 Q36424929-71B1B0CE-0713-4D23-8185-AC2A341A5EAE Q36441524-2951772E-663F-4800-9E63-BDAF1868ECA7 Q36458402-930DD318-8598-4B59-8F02-9D3C12C534D9 Q36491819-149A7AF1-AD97-43B9-8E37-F5FCC9330180 Q36593863-41E16A58-29E8-46B6-BF8D-458E202E0D58 Q36623050-E2C1C96B-DBCB-4CAF-AED0-A58101167ED9 Q36693843-F0556768-87FC-41DE-AA50-1EEA7F527937 Q36828156-6F2FFD2E-7A58-4122-AFE6-B4EDBE161857 Q36867925-2CB7CF51-C68C-40FD-9B17-C32C4511ABF7 Q36895679-5BC19226-7836-4BCC-9D31-B75BA3C9B2BB Q37124868-5AD408F5-F9A1-4190-882C-2E033571CA86

P2860

In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi

http://www.wikidata.org/entity/Q28343817

description

2000 nî lūn-bûn

@nan

2000 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2000 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2000年の論文

@ja

2000年論文

@yue

2000年論文

@zh-hant

2000年論文

@zh-hk

2000年論文

@zh-mo

2000年論文

@zh-tw

2000年论文

@wuu

name

In vitro activities of a new l ...... of clinically important fungi

@ast

In vitro activities of a new l ...... of clinically important fungi

@en

In vitro activities of a new l ...... of clinically important fungi

@nl

type

label

In vitro activities of a new l ...... of clinically important fungi

@ast

In vitro activities of a new l ...... of clinically important fungi

@en

In vitro activities of a new l ...... of clinically important fungi

@nl

prefLabel

In vitro activities of a new l ...... of clinically important fungi

@ast

In vitro activities of a new l ...... of clinically important fungi

@en

In vitro activities of a new l ...... of clinically important fungi

@nl

P1433

Q28343817-2BFA9881-EAF3-48FD-B140-400144BCAF1E

P1476

Q28343817-E99B40DF-DBA1-45C6-865C-5EBB13C20018

P2093

Q28343817-077785ED-B88B-4362-A11A-6FAD53B4E4FD

Q28343817-211F435E-6CC7-40D8-A99E-4BC28E60D701

Q28343817-38B0EF70-BF1C-4407-AABB-902927B9CC0B

Q28343817-3BF6C5E0-C944-47DC-A8A2-B0EDF6DF6F0B

Q28343817-3DFE420E-F58D-4EEC-A467-1F0A0747F058

Q28343817-46E2DE5A-71EC-4702-A21B-B422FD040DF3

Q28343817-64D60B70-05E1-4FEA-8E76-4A674A8A9F50

Q28343817-78AA9279-5C07-4488-9CD4-43C898E61649

Q28343817-86E9F110-2E56-4433-BD80-EB3276D33F07

Q28343817-A406EB70-EF57-47D4-85F0-A03B09926F89

P2860

Q28343817-0892CBBE-B7DB-496C-A55A-389E4AACBA59

Q28343817-15D676E5-3E65-4C12-B251-EAF9C2C4166D

Q28343817-356A6598-0654-4B52-8217-9A64819C34A5

Q28343817-3BFD1DBB-8F35-4D11-AFC0-450A7856CE7E

Q28343817-456DFD9C-D2DF-40C9-BBA4-C9DE5571DA42

Q28343817-4FCF4DCE-C635-4D54-85B7-9A91FAD74482

Q28343817-61419A67-E3CE-45F3-808A-B821DA35879D

Q28343817-77ECA3ED-F908-42FC-9EFD-8794115605AE

Q28343817-7AC751DC-893C-42B3-A4B6-33C5ADA616DD

Q28343817-7F83AE17-E65F-4AC5-ACAB-08F7FAB1F420

P304

Q28343817-EB48F88D-0CD0-4DA7-A018-97C76F412A20

P31

Q28343817-5BAC843F-1BE0-4E32-9C07-423D3D2DC0E2

P3181

Q28343817-559D0A6C-2050-40B7-BEE1-58331F4D4531

P356

Q28343817-791EFF49-B74B-407D-8A94-F1F303B454CE

P407

Q28343817-CA687946-756D-449A-9F7D-D4F63E3E6BE1

P433

Q28343817-CB8CB0F4-6F83-4EC0-A8E3-B56B88F46615

P478

Q28343817-309338EA-7FCA-4CF7-9584-9290E5562928

P577

Q28343817-39BE358B-F1DB-4769-8EAB-218F1D186ADF

P5875

Q28343817-917658FC-A8A2-4D32-92EC-21676744B17A

P698

Q28343817-2230281E-BF8F-4ED3-85C1-E61D29C4336E

P932

Q28343817-AD374F0F-8BA4-4D4F-8120-5B843EF1F0E3

P3181

P356

AAC.44.1.57-62.2000

P1433

Antimicrobial Agents and Chemotherapy

P1476

In vitro activities of a new l ...... of clinically important fungi

@en

P2093

A Yamada

http://www.w3.org/2001/XMLSchema#string

F Ikeda

http://www.w3.org/2001/XMLSchema#string

F Matsumoto

http://www.w3.org/2001/XMLSchema#string

H Ohki

http://www.w3.org/2001/XMLSchema#string

H Takasugi

http://www.w3.org/2001/XMLSchema#string

H Tanaka

http://www.w3.org/2001/XMLSchema#string

K Kawabata

http://www.w3.org/2001/XMLSchema#string

K Maki

http://www.w3.org/2001/XMLSchema#string

K Otomo

http://www.w3.org/2001/XMLSchema#string

K Sakane

http://www.w3.org/2001/XMLSchema#string

P2860

In vitro evaluation of the pneumocandin antifungal agent L-733560, a new water-soluble hybrid of L-705589 and L-731373

Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts

In vitro activity of the echinocandin antifungal agent LY303,366 in comparison with itraconazole and amphotericin B against Aspergillus spp.

Antifungal efficacy, safety, and single-dose pharmacokinetics of LY303366, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits.

In vitro activity of a new pneumocandin antifungal agent, L-733,560 against azole-susceptible and -resistant Candida and Torulopsis species

Comparison of the in vitro activities of the echinocandin LY303366, the pneumocandin MK-0991, and fluconazole against Candida species and Cryptococcus neoformans

In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872)

Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis

Efficacy of LY303366 against amphotericin B-susceptible and -resistant Aspergillus fumigatus in a murine model of invasive aspergillosis

In vitro activity of a new semisynthetic echinocandin, LY-303366, against systemic isolates of Candida species, Cryptococcus neoformans, Blastomyces dermatitidis, and Aspergillus species

P304

57-62

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4517218

http://www.w3.org/2001/XMLSchema#string

P356

10.1128/AAC.44.1.57-62.2000

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

44

http://www.w3.org/2001/XMLSchema#string

P577

2000-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

12698192

http://www.w3.org/2001/XMLSchema#string

P698

10602723

http://www.w3.org/2001/XMLSchema#string

P932

89628

http://www.w3.org/2001/XMLSchema#string